FDA

FDA admits heart drug doubles risk of death

Wednesday, July 27, 2011 by: J. D. Heyes
Tags: heart drugs, death risk, health news

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
The five biggest lies about Ebola being pushed by government and mass media
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Oregon man serving prison sentence for collecting rainwater on his own property
Russia taking McDonald's to court, threatens countrywide shutdown
Global warming data FAKED by government to fit climate change fictions
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
BREAKING: CDC whistleblower confesses to MMR vaccine research fraud in historic public statement
Monsanto's seed imperialism halted in Canada thanks to massive protests
Cannabis dissolves cancerous tumor in young infant, deemed a 'miracle baby' by physician
Top ten things you need to do NOW to protect yourself from an uncontrolled Ebola outbreak

Delicious
(NaturalNews) Regulators with the Food and Drug Administration have warned that Multaq, a cardiac drug Sanofi, has been linked with fatal heart problems in a clinical trial the company recently ended.

In the study involving 3,000 patients, 32 who were taking Multaq died from cardiac-related problems compared with 14 who were taking a placebo. In all, nearly twice as many people suffered heart attacks, strokes and death than those in the placebo control group.

Multaq is prescribed to control atrial fibrillation, the most common type of irregular heartbeat which is found in about 2.2 million Americans. It is a condition in which the primary electrical impulse that causes the atria - the two upper chambers of the heart - to contract instead fires erratically, causing several other nodes, or electrical impulse points, to fire instead.

The resulting erratic firing causes the atria to become inefficient, and heart rates can climb to about 150. The condition can lead to heart attacks or, more commonly, stroke, because blood does not flow through them as quickly, causing clots.

The Sanofi study involved patients who were 65 years old or older and who were afflicted with atrial fibrillation, or A-fib. The FDA approved Multaq for use in such patients in 2009 for a short-term type of the arrhythmia, as well as an associated condition known as atrial flutter.

As of June, some 241,000 patients nationwide had been prescribed twice-a-day Multaq. And while the FDA hasn't ordered the drug to be taken off the market, the agency is advising patients who are on it to talk to their doctor about the findings.

Despite the FDA warning, Sanofi says it believes the drug is still safe for use.

"It is important that Multaq only be used in patients with non-permanent atrial fibrillation or atrial flutter, as per the current U.S. label," a company spokesman told The Associated Press in an email.

The European Medicines Agency, which is similar in makeup and operation to the U.S. FDA, is also looking at the safety of Multaq, though that agency has yet to issue any warnings.

Recent studies have questioned the FDA's process for approving new drugs.

One study, published in the Journal of American Medical Association (JAMA) found that only about half of the drugs put on the market over the past decade had proper data in place for the FDA, yet the agency approved them anyway, while others - like aripiprazole, used to treat bipolar disorder - were approved after only limited clinical trials.

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.